MX2024007090A - Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. - Google Patents

Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.

Info

Publication number
MX2024007090A
MX2024007090A MX2024007090A MX2024007090A MX2024007090A MX 2024007090 A MX2024007090 A MX 2024007090A MX 2024007090 A MX2024007090 A MX 2024007090A MX 2024007090 A MX2024007090 A MX 2024007090A MX 2024007090 A MX2024007090 A MX 2024007090A
Authority
MX
Mexico
Prior art keywords
receptor alpha
canine
canine interleukin
caninized antibodies
antibodies
Prior art date
Application number
MX2024007090A
Other languages
English (en)
Spanish (es)
Inventor
Mohamad Morsey
Yuanzheng Zhang
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024007090A publication Critical patent/MX2024007090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024007090A 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. MX2024007090A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163290256P 2021-12-16 2021-12-16
US202163290259P 2021-12-16 2021-12-16
US202263341443P 2022-05-13 2022-05-13
PCT/EP2022/086040 WO2023111128A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha ii

Publications (1)

Publication Number Publication Date
MX2024007090A true MX2024007090A (es) 2024-08-22

Family

ID=84923386

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024007090A MX2024007090A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
MX2024007089A MX2024007089A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024007089A MX2024007089A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.

Country Status (7)

Country Link
US (2) US20250340653A1 (https=)
EP (2) EP4448571A1 (https=)
JP (2) JP2024546759A (https=)
AU (2) AU2022409610A1 (https=)
CA (2) CA3239826A1 (https=)
MX (2) MX2024007090A (https=)
WO (2) WO2023111148A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
MX2022007636A (es) * 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.

Also Published As

Publication number Publication date
US20250340654A1 (en) 2025-11-06
EP4448572A1 (en) 2024-10-23
CA3239307A1 (en) 2023-06-22
JP2024546763A (ja) 2024-12-26
MX2024007089A (es) 2024-08-22
WO2023111148A1 (en) 2023-06-22
EP4448571A1 (en) 2024-10-23
AU2022409603A1 (en) 2024-06-27
US20250340653A1 (en) 2025-11-06
CA3239826A1 (en) 2023-06-22
WO2023111128A1 (en) 2023-06-22
AU2022409610A1 (en) 2024-05-30
JP2024546759A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
MX2023004439A (es) Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina.
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
EP3954710A3 (en) Antibodies to canine interleukin-4 receptor alpha
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MX2024007090A (es) Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
PH12021552538A1 (en) Heavy chain antibodies binding to psma
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
TN2019000086A1 (en) Anti-il-33 antibodies and uses thereof
MX2022007677A (es) Anticuerpos para receptor alfa de interleucina-4 canino.
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
ZA201807816B (en) Anti-il-22r antibodies
MX2024011444A (es) Anticuerpos anti-npr1 y usos de los mismos.
IL288607A (en) High affinity anti-cd3 antibodies and methods for their creation and use
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
TN2018000289A1 (en) Antibodies for il-17c
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2020006125A (es) Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer.
ZA202401100B (en) Human interleukin-4 receptor alpha antibodies
MX2022016494A (es) Anticuerpos anti-il13ra2.
ZA202104048B (en) Anti-il-17a antibody and use thereof
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.